Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.

Abstract

The efficacy and field safety of marbofloxacin (Zeniquin) for the treatment of superficial and deep bacterial pyoderma were evaluated. Seventy-two dogs were treated with 2.75 mg kg-1 of marbofloxacin orally once daily for 21 or 28 days. Sixty-two dogs (86%) had superficial pyoderma and 10 (14%) had deep pyoderma. A history of prior pyoderma was reported in 39/72 dogs. Pretreatment aerobic bacteriologic cultures of skin lesions were performed in 47 cases and the predominant pathogen isolated was Staphylococcus intermedius. Treatment was successful in 62/72 (86.1%) dogs, improvement was noted in 6/72 (8.3%) dogs and treatment failed in 4/72 (5.6%) dogs. Adverse effects associated with treatment included listlessness, anorexia, vomiting, soft stool, flatulence and polydipsia; these adverse effects were seen in only 6/81 dogs. Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study.

• Authors: M Paradis, L Abbey, B Baker, M Coyne, M Hannigan, D Joffe, B Pukay, A Trettien, S Waisglass, J Wellington
• Journal: Veterinary dermatology (Vet Dermatol) Vol. 12 Issue 3 Pg. 163-9 (Jun 2001) ISSN: 0959-4493 [Print] England
• PMID: 11420932 (Publication Type: Evaluation Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Quinolones
• marbofloxacin

Topics

• Administration, Oral
• Animals
• Anti-Infective Agents (administration & dosage, therapeutic use)
• Breeding
• Canada
• Dog Diseases (drug therapy)
• Dogs
• Female
• Fluoroquinolones
• Male
• Pyoderma (drug therapy, veterinary)
• Quinolones (administration & dosage, therapeutic use)
• Severity of Illness Index
• Staphylococcal Infections (drug therapy, veterinary)
• Treatment Outcome